These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 26341171)
1. Insulin dosing and outcomes among commercially insured patients with type 2 diabetes in the United States. Eby EL; Van Brunt K; Brusko C; Curtis B; Lage MJ Clin Ther; 2015 Oct; 37(10):2297-2308.e1. PubMed ID: 26341171 [TBL] [Abstract][Full Text] [Related]
2. Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes. Eby EL; Van Brunt K; Brusko C; Curtis B; Lage MJ Clin Interv Aging; 2015; 10():991-1001. PubMed ID: 26124652 [TBL] [Abstract][Full Text] [Related]
3. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Cobden D; Lee WC; Balu S; Joshi AV; Pashos CL Pharmacotherapy; 2007 Jul; 27(7):948-62. PubMed ID: 17594200 [TBL] [Abstract][Full Text] [Related]
4. The burden of severe hypoglycemia in type 1 diabetes. Liu J; Wang R; Ganz ML; Paprocki Y; Schneider D; Weatherall J Curr Med Res Opin; 2018 Jan; 34(1):171-177. PubMed ID: 29019269 [TBL] [Abstract][Full Text] [Related]
5. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122 [TBL] [Abstract][Full Text] [Related]
6. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128 [TBL] [Abstract][Full Text] [Related]
7. The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study. Eby EL; Boye KS; Lage MJ J Med Econ; 2013 Oct; 16(10):1231-7. PubMed ID: 23834480 [TBL] [Abstract][Full Text] [Related]
8. The burden of severe hypoglycemia in type 2 diabetes. Liu J; Wang R; Ganz ML; Paprocki Y; Schneider D; Weatherall J Curr Med Res Opin; 2018 Jan; 34(1):179-186. PubMed ID: 29017368 [TBL] [Abstract][Full Text] [Related]
9. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis. Eby EL; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA J Med Econ; 2013; 16(4):529-38. PubMed ID: 23363330 [TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of medical costs and resource utilization for severe hypoglycemic events in patients with type 2 diabetes in Japan. Ikeda Y; Kubo T; Oda E; Abe M; Tokita S J Diabetes Investig; 2019 May; 10(3):857-865. PubMed ID: 30325576 [TBL] [Abstract][Full Text] [Related]
11. Health care resource utilization and cost of severe hypoglycemia treatment in insulin-treated patients with diabetes in the United States. Bajpai S; Wong-Jacobson S; Liu D; Mitchell B; Haynes G; Syring K; Ali AK; Chinthammit C J Manag Care Spec Pharm; 2021 Mar; 27(3):385-391. PubMed ID: 33645242 [No Abstract] [Full Text] [Related]
12. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. Williams SA; Shi L; Brenneman SK; Johnson JC; Wegner JC; Fonseca V J Diabetes Complications; 2012; 26(5):399-406. PubMed ID: 22699113 [TBL] [Abstract][Full Text] [Related]
13. Medication adherence and improved outcomes among patients with type 2 diabetes. Curtis SE; Boye KS; Lage MJ; Garcia-Perez LE Am J Manag Care; 2017 Jul; 23(7):e208-e214. PubMed ID: 28850793 [TBL] [Abstract][Full Text] [Related]
14. Severe hypoglycemia rates and associated costs among type 2 diabetics starting basal insulin therapy in the United States. Ganz ML; Wintfeld NS; Li Q; Lee YC; Gatt E; Huang JC Curr Med Res Opin; 2014 Oct; 30(10):1991-2000. PubMed ID: 24945720 [TBL] [Abstract][Full Text] [Related]
15. Healthcare resource use, direct and indirect costs of hypoglycemia in type 1 and type 2 diabetes, and nationwide projections. Results of the HYPOS-1 study. Giorda CB; Rossi MC; Ozzello O; Gentile S; Aglialoro A; Chiambretti A; Baccetti F; Gentile FM; Romeo F; Lucisano G; Nicolucci A; Nutr Metab Cardiovasc Dis; 2017 Mar; 27(3):209-216. PubMed ID: 28017523 [TBL] [Abstract][Full Text] [Related]
16. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States. Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133 [TBL] [Abstract][Full Text] [Related]
17. Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US. Perez-Nieves M; Kabul S; Desai U; Ivanova JI; Kirson NY; Cummings AK; Birnbaum HG; Duan R; Cao D; Hadjiyianni I Curr Med Res Opin; 2016; 32(4):669-80. PubMed ID: 26703951 [TBL] [Abstract][Full Text] [Related]
18. Healthcare resource use and associated costs of hypoglycemia in patients with type 2 diabetes prescribed sulfonylureas. Alemayehu B; Liu J; Rajpathak S; Engel SS J Diabetes Complications; 2017 Nov; 31(11):1620-1623. PubMed ID: 28844830 [TBL] [Abstract][Full Text] [Related]
19. Predictors of emergency department and outpatient visits for hypoglycemia in type 2 diabetes: an analysis of a large US administrative claims database. Simeone JC; Quilliam BJ Ann Pharmacother; 2012 Feb; 46(2):157-68. PubMed ID: 22234990 [TBL] [Abstract][Full Text] [Related]
20. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis. Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]